Gilead's weekly oral lenacapavir PrEP pill faces FDA decision Feb. 2, 2027
The sNDA leans on injectable Yeztugo's already-established PURPOSE 1 and PURPOSE 2 efficacy data, so the decision turns on whether a daily pill matches that bar, not on new trial results.
Executive Summary
- Gilead is awaiting an FDA decision on an oral, once-weekly version of a drug already approved as a twice-yearly injectable for the same use, so the review tests formulation bridging rather than a new efficacy question.
- The application leans entirely on efficacy data already generated for the injectable version, meaning the regulatory question is whether that data package extends cleanly to a pill rather than whether the drug works.
- No other capsid inhibitor has reached Phase 3 in HIV prevention, leaving lenacapavir as the only asset of its mechanism at this stage in the indication.
- A clearance would not introduce a new HIV-prevention option so much as add a self-administered oral form to a franchise already validated by regulators, expanding choice within the same mechanism rather than the field.
The filing
The FDA accepted Gilead's supplemental New Drug Application for Yeztugo (lenacapavir) 300-mg tablet as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis on June 15, 2026, and assigned a PDUFA action date of February 2, 2027. Gilead Chief Medical Officer Dietmar Berger said the filing builds on the injectable drug's established profile to "extend the impact of our long-acting innovation into new formulations," nearly a year after the twice-yearly injection's approval. If cleared, once-weekly oral Yeztugo would become an oral option in the same regimen family as the approved injectable, rather than a first entry into HIV prevention. U.SU.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionJun 15, 2026
The evidence base
The sNDA cites results from the Phase 3 PURPOSE 1 and PURPOSE 2 trials as its supporting package, the same data that carried the injectable formulation's approval, covering cisgender women, cisgender men and gender-diverse populations. PURPOSE 2, registered as NCT04925752, enrolled 3,292 participants across sites in the United States, Brazil, Thailand, South Africa, Peru, Argentina, Puerto Rico and Mexico, and is Active, not recruiting, having posted results on September 17, 2025. Its primary endpoint measured background HIV-1 incidence against a Recent Infection Testing Algorithm estimate rather than a fresh efficacy metric for the oral tablet, since the oral form was not itself the tested intervention in this trial. The oral tablet is already approved as a loading dose and bridge therapy within the injectable Yeztugo regimen, giving the FDA prior human exposure data on the same formulation ahead of this standalone PrEP review. U.S+1U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionJun 15, 2026Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV InfectionNCT04925752
Regulatory posture
Lenacapavir carries a Breakthrough Therapy Designation from the FDA for PrEP, granted in October 2024 ahead of the injectable's approval the following June, and the drug's twice-yearly form is now approved in multiple countries. The registry shows the trial's primary completion date shifted four times between 2023 and 2025, most recently landing on August 21, 2024, a pattern consistent with a program that has moved from active enrollment through results posting rather than one still generating new efficacy signals ahead of this filing. U.S+1U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionJun 15, 2026Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV InfectionNCT04925752
Where lenacapavir sits
No other capsid inhibitor has reached Phase 3 in HIV pre-exposure prophylaxis, and only three active trials study the HIV-1 capsid protein target in this indication, making lenacapavir the only asset of its mechanism at this stage of development here. The nearest oral comparators in PrEP work through different targets, including tenofovir alafenamide and emtricitabine against HIV-1 reverse transcriptase and cabotegravir against HIV-1 integrase, none of which share lenacapavir's capsid-inhibitor mechanism. Given that isolation, the decision that would matter most is whether the FDA accepts the injectable's efficacy data as sufficient bridging evidence for a chemically related oral tablet, since no other approved PrEP option has made that specific formulation jump within the same mechanism. U.SU.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionJun 15, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.